7:45 AM - 8:45 AM

Registration and Breakfast in the AI Café

8:45 AM - 9:00 AM

Chair's Opening Remarks: Where You Are Headed, You Can't Go It Alone

In this opening session, Harry will set the stage for the discussions that will take place over the course of the Summit and identify the key questions that need to be asked and answered. What organizational structures will produce the best results? Should you partner or make acquisitions? How do you best structure post-acquisition assets? How do you make the cultural shift to change workflows around the technology to get real benefit for the AI tools, instead of trying to fit technology into existing workflows? And most importantly, how do you identify the problems the technology is best suited to solve? Wherever you are on the road to AI adoption, you can’t go it alone so join the conversation and help drive the movement forward.

9:00 AM - 9:25 AM

Positioning your Organization to Succeed: The Urgency to Advance AI-based Innovations to Bring its Benefits to Patients Faster

AI in R&D

9:25 AM - 9:50 AM

Achieving Near Term ROI using AI and Machine Learning in Life Sciences R&D

Having been burnt many times in the past, the life science industry is moving cautiously in its adoption of AI and machine learning technologies.  Beyond comprehensive validation, leading innovators in the industry are also requiring clear, quantifiable benefits from AI solutions.  In this session, we hope to highlight the spectrum of AI opportunities, measured progress to date, and opportunities to systematically move forward.

9:50 AM - 10:20 AM

AI Applications for Identifying New Drug Candidates

Your CEO knows the company needs to adopt AI/ML technology, but they don't want to get involved in the details.  You now have the budget, but you need to produce an ROI.  What are your options when it comes to using AI tools to identify new drug candidates?  AI has the potential to become an indispensable tool but only if the near-term ROI is realized.  What questions do you need to ask to get this right and make a difference in speed, cost and outcomes?


10:20 AM - 10:50 AM

Harnessing the Power of AI to Generate Novel Drug Candidates Using Patient-Driven Biology

The opportunity to improve health outcomes by using a collaborative and AI-enabled targeted approach to drug discovery and development is upon us.  In this session, Niven will address the biggest challenges still ahead that the healthcare community needs to address and what can be accomplished by starting and ending with patient-driven biology.

10:50 AM - 11:20 AM

Networking Refreshments & Analyst One-to-One Meetings

AI Café

11:20 AM - 11:50 AM

Deploying AI Tools to Accelerate Each Step in the Drug Discovery Pipeline

While we may still be a decade away from fully in silico drug discovery, AI has proven to have vast potential in this area.  Expanding and accelerating traditional approaches like phenotypic screening provide a feasible near-term solution to bringing substantial improvements to the efficiency of discovery and development efforts.  This session will describe technical strategies to accelerate discovery using AI, including an image-based phenotypic screening platform.  The use of deep learning models to build predictive tools for multiple stages in the drug discovery pipeline will also be discussed.

11:50 AM - 12:20 AM

Opportunities and Challenges Using AI in unlocking the ADME Tox Obstacles in Drug Development

This session will address how machine and active learning are being applied to solve complex and difficult ADME Tox problems facing the pharma industry.  There will be representation from both in-house and external models as well as pro and con viewpoints on applying AI to the challenges of the ADME/tox field.  Industry innovators and researchers share their efforts in solving these challenges which could be worth hundreds of millions to industry, accelerate drug discovery and be invaluable to patients.



12:20 PM - 1:20 PM

Networking Lunch & Analyst One-to One Meetings

AI Café

1:20 PM - 1:50 PM

Applying AI to Accelerate Drug Discovery & Design from Patient Data to Drug

A survey of methods that can be sued to discover novel targets from patient data, validate those targets from literature mining and drug safety data, design novel leads for those targets and insure that the lead candidate has good drug like properties – all enhanced with a variety of AI methods to be presented.

1:50 PM - 2:20 PM

Data, Technology, and Innovation: Utility Within the Global Regulatory Environment

This session will focus on the importance of data quality and integrity to support technology and innovation within the regulatory environment.  Data is often overlooked as an extremely valuable asset within an organization subjected to manual processes for entry, exchange, and overall management.  These manual processes coupled with the lack of a formal data governance framework introduces human interpretation and bias which may increase the risk profile for regulatory decision-making and erode confidence and trust in the utility of innovative technologies, such as AI.
  • Vada A. Perkins

    Vada A. Perkins Director, Regulatory Policy & Intelligence, Bayer Pharmaceuticals

AI in Clinical Trials

2:20 PM - 2:50 PM

Clinical Trial Design

2:50 PM - 3:20 PM

Afternoon Refreshments & Analyst One-to-One Meetings

AI Café

3:20 PM - 3:50 PM

Patient Selection, Recruitment & Retention

3:50 PM - 4:10 PM

Optimizing Clinical Trials

4:10 PM - 4:30 PM

Fireside Chat: Getting Corporate Culture Right to Improve Business Outcome Conversations and Results

4:30 PM - 5:00 PM

Innovation Spotlight ChangeMaker Presentations

How much can you learn in five minutes? Quite a bit. Hear quick hitting presentations on the latest products, new releases, exciting innovations, and more. Each presenter will speak for 5 minutes and then will be available to answer questions during the reception.



5:00 PM - 6:00 PM

Evening Reception

AI Café